Lymphoma
Biomira Initiates Exploratory Phase Ib Trial With Patient-Specific Cancer Vaccines
Published in Cancer Weekly, October 9th, 2001
Biomira USA, a subsidiary of Biomira Inc., has initiated a Phase Ib clinical trial to test safety and immunogenicity of an autologous vaccine strategy for the treatment of B-cell lymphoma. This program, carried out under a Collaborative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), is the second step in the investigation of an autologous vaccine strategy based on a liposomal formulation.
In the first step, carried out at NCI under the direction of Dr. Larry Kwak, the study showed that a highly purified patient-specific cancer antigen could be produced and formulated by a patented process into a liposomal formulation that also...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2001-10-09)
More Articles from Cancer Weekly
- Adult T-Cell Leukemia
Lung-Resistance Related Protein Linked To Poor Prognosis - Cancer Therapy
Immunological Gene Therapy And Tumor Debulking Delays Mesothelioma Growth - Breast Cancer
Scientist Identify High Resolution Of BRAC1 Protein - Cancer Gene Therapy
Gene That Prevents Tumor Growth Also Carries Messages From Circadian Clock - Carcinogens
Hepatitis C A Major Cause Of Cancers In Italian Population - Multiple Myeloma
Lymphocyte Infusions After Bone Marrow Grafts Effective But Dangerous - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
